Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 13;8(7):e106.
doi: 10.1038/ctg.2017.33.

Fistulizing Crohn's Disease

Affiliations

Fistulizing Crohn's Disease

Michael Scharl et al. Clin Transl Gastroenterol. .

Abstract

Fistulas still represent one of the most important complications in patients with Crohn's disease (CD). At least one third of CD patients suffer from fistulas during their disease course and amongst them longstanding remission of complex fistulas occurs only in about one third. So far, fistula pathogenesis is only partially understood. From a histopathological view, a fistula is a tube covered by flat epithelial cells. Current research suggests that the driving force for fistula development is epithelial-to-mesenchymal transition (EMT). Around the fistula, high levels of tumor necrosis factor (TNF), IL-13, and TGFβ can be detected and recent studies indicated an involvement of the intestinal microbiota. Fistula diagnosis requires clinical and surgical assessment, radiologic investigations, e.g., magnet resonance imaging and endoscopy. Routine medical treatment of fistulas includes antibiotics, immunosuppressives, and anti-TNF antibodies. There is no well-established role for calcineurin inhibitors in fistula treatment, corticosteroids appear to be even contra-productive. A promising novel approach might be the application of adipose tissue-derived or bone marrow-derived mesenchymal stem cells that have been studied recently. Due to insufficient efficacy of medical treatment and recurrence of fistulas, surgical interventions are frequently necessary. Further research is needed to better understand fistula pathogenesis aiming to develop novel treatment option for our patients.

PubMed Disclaimer

Conflict of interest statement

Guarantor of the article: Michael Scharl, MD.

Specific author contributions: All authors participated sufficiently, intellectually, or practically in the work to take public responsibility for the content of the article, including the conception, design, data interpretation, and writing of the manuscript. The final version of the manuscript was approved by all authors.

Financial support: No study sponsors had any involvement in study design, data collection, interpretation, or writing of the manuscript.

Potential competing interests: Gerhard Rogler has consulted to Abbot, Abbvie, Augurix, Boehringer, Calypso, FALK, Ferring, Fisher, Genentech, Essex/MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions, and Zeller; received speaker’s honoraria from Astra Zeneca, Abbott, Abbvie, FALK, MSD, Phadia, Tillots, UCB, and Vifor; received educational grants and research grants from Abbot, Abbvie, Ardeypharm, Augurix, Calypso, Essex/MSD, FALK, Flamentera, Novartis, Roche, Takeda, Tillots, UCB, and Zeller. Michael Scharl has received speaker’s honoraria from FALK.

Figures

Figure 1
Figure 1
Pathogenesis of Crohn’s disease-associated fistulae. Due to an epithelial barrier defect several pathogen-associated molecular patterns (PAMPs), like e.g., muramyl-dipeptide (MDP), as well as bacteria are able to enter the gut mucosa. The resulting inflammatory response induces the event of epithelial-to-mesenchymal transition (EMT). First, an increased expression of tumor necrosis factor (TNF) is initiated, resulting in an upregulation of TGF-β production. This triggers a signaling cascade of molecules associated with matrix remodeling, in particular enhanced activity of matrix metalloproteinases (MMPs) and cell invasiveness, such as β6-Integrin. These events favor the transformation of the intestinal epithelial cells (IECs) towards invasive myofibroblast like cells, what finally results in fistula formation.

Similar articles

Cited by

References

    1. Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. Ann Surg 1938; 108: 867–873. - PMC - PubMed
    1. Schwartz DA et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875–880. - PubMed
    1. Peyrin-Biroulet L et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289–297. - PubMed
    1. Cosnes J et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244–250. - PubMed
    1. Gower-Rousseau C et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis 2013; 45: 89–94. - PubMed